Published in

American Society of Clinical Oncology, JCO Precision Oncology, 5, p. 687-694, 2021

DOI: 10.1200/po.20.00278

Links

Tools

Export citation

Search in Google Scholar

Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient WithETV6-NTRK3Fusion-Positive Carcinoma Harboring theNTRK3<sup>G623R</sup>Solvent-Front Mutation

Journal article published in 2021 by Dorothea Hanf ORCID, Christoph Heining, Karin Laaber ORCID, Heiner Nebelung ORCID, Sebastian Uhrig ORCID, Barbara Hutter, Arne Jahn ORCID, Daniela Richter, Daniela Aust ORCID, Friederike Herbst ORCID, Stefan Fröhling ORCID, Hanno Glimm, Gunnar Folprecht ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO